Literature DB >> 28449972

Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.

Arijit Sil1, Mandyam D Ravi2, Badri N Patnaik3, Mandeep S Dhingra4, Martin Dupuy5, Dulari J Gandhi6, Sangappa M Dhaded7, Anand P Dubey8, Ritabrata Kundu9, Sanjay K Lalwani10, Jugesh Chhatwal11, Leni G Mathew12, Madhu Gupta13, Shiv D Sharma14, Sandeep B Bavdekar15, Soumya P Rout3, Midde V Jayanth3, Naveena A D'Cor3, Somnath A Mangarule3, Suresh Ravinuthala3, Jagadeesh Reddy E3.   

Abstract

BACKGROUND: Vaccination is considered as the most cost effective method for preventing infectious diseases. Low grade fever is a known adverse effect of vaccination. In India, it is a common clinical practice to prescribe paracetamol either prophylactically or therapeutically to manage fever. Some studies have shown that paracetamol interferes with antibody responses following immunization. This manuscript reports the outcome of a post hoc analysis of data from a clinical trial of a pentavalent vaccine in Indian infants where paracetamol was not used or was used either as prophylaxis or for treatment of fever.
METHODS: Pre and post vaccine antibody levels against Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type B were assessed in no paracetamol and paracetamol groups. The paracetamol group was further divided into prophylactic and treatment groups.
RESULTS: Similar rates of seroprotection/seroresponse for anti-D, anti-T, anti-wP, anti-PT, anti-HBs and anti-PRP were observed in all the groups. There was no clear tendency for difference in percentage seroprotection/seroresponse and geometric mean (GM) titers in any of the groups.
CONCLUSION: The study found no evidence that paracetamol usage either as prophylactic or for treatment impact immunological responses to DTwP-HepB-Hib combination vaccine. [Clinical trial registry of India (study registration number CTRI/2012/08/002872)].
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Immunogenicity; India; Paracetamol; Pentavalent; Prophylactic; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28449972     DOI: 10.1016/j.vaccine.2017.03.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Immune Response of Indian Preterm Infants to Pentavalent Vaccine Varies With Component Antigens and Gestational Age.

Authors:  Archana Kulkarni-Munje; Nandini Malshe; Sonali Palkar; Aniket Amlekar; Sanjay Lalwani; Akhilesh Chandra Mishra; Vidya Arankalle
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

Review 2.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

Review 3.  Let fever do its job: The meaning of fever in the pandemic era.

Authors:  Sylwia Wrotek; Edmund K LeGrand; Artur Dzialuk; Joe Alcock
Journal:  Evol Med Public Health       Date:  2020-11-23

Review 4.  Effect of prophylactic administration of antipyretics on the immune response to pneumococcal conjugate vaccines in children: a systematic review.

Authors:  Eleni Koufoglou; Georgia Kourlaba; Athanasios Michos
Journal:  Pneumonia (Nathan)       Date:  2021-04-25

5.  Adverse events following pediatric immunization in an Indian city.

Authors:  Varun Paramkusham; Prashanth Palakurthy; Navya Sri Gurram; Varun Talla; Hunsur Nagendra Vishwas; Venkateshwar Rao Jupally; Satyanarayan Pattnaik
Journal:  Clin Exp Vaccine Res       Date:  2021-09-30

Review 6.  Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination.

Authors:  Eng Eong Ooi; Arti Dhar; Richard Petruschke; Camille Locht; Philippe Buchy; Jenny Guek Hong Low
Journal:  NPJ Vaccines       Date:  2022-03-02       Impact factor: 9.399

7.  Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.

Authors:  S Mangarule; S Prashanth; A Kawade; M D Ravi; I V Padmavathi; S Palkar; V N Tripathi; R Singh; M Maurya; M Mitra; R S Shetty; R Z Kompithra; S M Dhaded; V Epari; A Moureau; M V Jayanth; K Varghese; S Ravinuthala; D Kukian; B N Patnaik; F Noriega
Journal:  Vaccine X       Date:  2022-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.